Ellevest Inc’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ellevest Inc’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	–	–	1606
2021 Q4	$0	Buy	+10	New	+$112	﹤0.01%	1617

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ellevest Inc's RYTM Position: Q1 2022 in Review

Ellevest Inc sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2022, closing a stake of 10 shares.

Ellevest Inc first reported a position in RYTM in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 111 funds tracked by Wall St. Rank hold RYTM as of Q1 2022.

Ellevest Inc reported no remaining Rhythm Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Ellevest Inc sold 10 Rhythm Pharmaceuticals shares in Q1 2022.
Ellevest Inc first reported a position in Rhythm Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Ellevest Inc's Rhythm Pharmaceuticals position peaked at $0 in Q4 2021.
111 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2022.

Based on Ellevest Inc's 13F filing for Q1 2022, filed 19 Apr 2022.